HDAC9 and central nervous system cancer: A combination of CUDC-907 (a dual HDAC/PI3K inhibitor) and radiotherapy has shown synergistic antitumor activity on c-Myc-amplified BT245 and SF188 glioma cell lines, downregulating NF-κB and FOXM1 expression and transcriptional activity, blocking DNA repair, enhancing radiosensitization in glioma cells, and activating apoptosis [407].